Inovio (NASDAQ: INO) awards CSO stock options and RSUs grant

Rhea-AI Filing Summary

Humeau Laurent reported acquisition or exercise transactions in this Form 4 filing.

INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported equity awards on common stock on March 4, 2026. He received a grant of 26,840 stock options vesting in three annual installments on February 26 of 2027, 2028 and 2029. He also received 21,560 restricted stock units, which vest in similar annual tranches from February 26, 2027 through February 26, 2029 and represent contingent rights to receive common shares, cash or a combination of both upon vesting.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Humeau Laurent

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Option	26,840	$0.00	--
Grant/Award	Restricted Stock Unit	21,560	$0.00	--

Holdings After Transaction: Common Stock Option — 26,840 shares (Direct); Restricted Stock Unit — 21,560 shares (Direct)

Footnotes (1)

1. The vesting schedule for the 26,840 options granted on March 4, 2026 was as follows: 8,947 shares will vest on February 26, 2027; 8,947 shares will vest on February 26, 2028; 8,946 shares will vest on February 26, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 21,560 restricted stock units granted on March 4, 2026 was as follows: 7,187 shares will vest on February 26, 2027; 7,187 shares will vest on February 26, 2028; and 7,186 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Humeau Laurent

(Last) (First) (Middle)

C/O INOVIO PHARMACEUTICALS, INC.

6769 MESA RIDGE RD.

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	$1.73	03/04/2026		A		26,840		(1)	02/26/2036	Common Stock	26,840	$0	26,840	D
Restricted Stock Unit	(2)	03/04/2026		A		21,560		(2)	(2)	Common Stock	21,560	$0	21,560	D

Explanation of Responses:

1. The vesting schedule for the 26,840 options granted on March 4, 2026 was as follows: 8,947 shares will vest on February 26, 2027; 8,947 shares will vest on February 26, 2028; 8,946 shares will vest on February 26, 2029.

2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 21,560 restricted stock units granted on March 4, 2026 was as follows: 7,187 shares will vest on February 26, 2027; 7,187 shares will vest on February 26, 2028; and 7,186 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Remarks:

	/s/ Laurent Humeau	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did INO Chief Scientific Officer Laurent Humeau report?

Laurent Humeau reported equity awards consisting of stock options and restricted stock units. He received 26,840 common stock options and 21,560 restricted stock units on March 4, 2026, both subject to multi-year vesting schedules ending in 2029.

How do the 26,840 stock options granted to INO’s CSO vest?

The 26,840 stock options vest in three equal annual installments. 8,947 options vest on February 26, 2027, another 8,947 on February 26, 2028, and the remaining 8,946 options on February 26, 2029, subject to the award terms.

What are the terms of the 21,560 restricted stock units granted to INO’s CSO?

Each of the 21,560 restricted stock units represents a contingent right to receive one common share. Vesting occurs in three tranches: 7,187 units on February 26, 2027, 7,187 on February 26, 2028, and 7,186 on February 26, 2029, with settlement in shares, cash, or both.

Are the INO equity awards to Laurent Humeau direct or indirect holdings?

The reported equity awards to Laurent Humeau are held as direct ownership. Both the stock options and restricted stock units are coded as direct, indicating they are attributed directly to him rather than through an intermediate entity.

Does Laurent Humeau’s INO Form 4 show any stock sales or dispositions?

The Form 4 shows only award acquisitions, not sales or dispositions. It reports two grant-type transactions coded as awards: one for stock options and one for restricted stock units, both increasing his derivative equity position.